Alivus Life Sciences Ltd

Alivus Life Sciences Q3 Results: Record Revenue & Margin Growth 📈

- Q3 revenue: Rs. 673 crores, up 14.4% QoQ and 4.8% YoY

- EBITDA margin reached record 36.4% in Q3, up 510 bps YoY

- CDMO business grew 100% QoQ and 85.3% YoY

- High single-digit revenue growth guidance maintained for FY'26

- EBITDA margin expectations raised to 30%-32% from 28%-30%

- CAPEX reduced to Rs. 450 crores for FY'26 from Rs. 600 crores, with Rs. 150 crores deferred to FY'27

- R&D expenditure: Rs. 23 crores (3.4% of sales) in Q3

- Capacity expansions at Solapur, Ankleshwar, and Dahej progressing; Solapur expected by July 2026 after 3-month delay

- Pipeline includes 595 DMF and CEP filings globally

- High-potency API portfolio targeting $70 billion market